Proteomic analysis of urinary biomarker candidates for nonmuscle invasive bladder cancer
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Nonmuscle invasive tumors of the bladder often recur and thereby bladder cancer patients need regular re‐examinations which are invasive, unpleasant, and expensive. A noninvasive and less expensive method, e.g. a urine dipstick test, for monitoring recurrence would thus be advantageous. In this study, the complementary techniques mass spectrometry (MS) and Western blotting (WB)/dot blot (DB) were used to screen the urine samples from bladder cancer patients. High resolving MS was used to analyze and quantify the urinary proteome and 29 proteins had a significantly higher abundance (p<0.05) in bladder cancer samples compared with control urine samples. The increased abundance found in urine from bladder cancer patients compared with controls was confirmed with Western blot for four selected proteins; fibrinogen β chain precursor, apolipoprotein E, α‐1‐antitrypsin, and leucine‐rich α‐2‐glycoprotein 1. Dot blot analysis of an independent urine sample set pointed out fibrinogen β chain and α‐1‐antitrypsin as most interesting biomarkers having sensitivity and specificity values in the range of 66–85%. Exploring the Human Protein Atlas (HPA) also revealed that bladder cancer tumors are the likely source of these proteins. They have the potential of being useful in diagnosis, monitoring of recurrence and thus may improve the treatment of bladder tumors, especially nonmuscle invasive tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human plasma fibrinogen is synthesized in the liver
Tennent, G. A., Brennan, S. O., Stangou, A. J., O'Grady, J., Hawkins, P. N., & Pepys, M. B. (2007) · Blood · doi:10.1182/blood-2006-08-040956 · Cited by 304
Apolipoprotein E is required for cell proliferation and survival in ovarian cancer
Chen, Y.-C., Pohl, G., Wang, T.-L., Morin, P. J., Risberg, B., Kristensen, G. B., Yu, A., Davidson, B., & Shih, I.-M. (2005) · Cancer Research · doi:10.1158/0008-5472.331.65.1 · Cited by 155 · cited 1×
“Among the other validated proteins, the apolipoprotein APOE has been reported to be elevated in ovarian cancers compared with normal tissue, and also gene expression analyses showed overexpression of APOE in several different cancer types [19].”
Background
Cited by
A multi-analyte assay for the non-invasive detection of bladder cancer
Goodison, S., Chang, M., Dai, Y., Urquidi, V., & Rosser, C. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047469 · Cited by 109
“reported that APOE was a component of a panel of biomarkers detected by mass spectroscopy, and may be associated with non-muscle invasive BCa [28].”
BackgroundA secretagogin locus of the mammalian hypothalamus controls stress hormone release
Romanov, R. A., Alpár, A., Zhang, M., Zeisel, A., Calas, A., Landry, M., Fuszard, M., Shirran, S. L., Schnell, R., Dobolyi, Á., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201488977 · Cited by 85
Developing proteomic biomarkers for bladder cancer: towards clinical application
Frantzi, M., Latosinska, A., Flühe, L., Hupe, M. C., Critselis, E., Kramer, M. W., Merseburger, A. S., Mischak, H., & Vlahou, A. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.100 · Cited by 83
Metadata
- Authors
- Lindén, M., Lind, S. B., Mayrhofer, C., Segersten, U., Wester, K., Lyutvinskiy, Y., Zubarev, R., Malmström, P., & Pettersson, U.
- Venue
- PROTEOMICS
- Publisher
- Wiley
- Published
- 2011-12-02
- Volume
- 12
- Issue
- 1
- Pages
- 135-144
- ISSN
- 1615-9853 (ISSN-L)
- 1615-9861
- OpenAlex
- W2153861174
- Cited by
- 97
- References
- 2
- FWCI
- 7.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.